EUVIMEDEUVIMED entdecken
Crossref

Novel CXCR4-Targeted Radioligands with Improved Tumor Uptake and Therapeutic Efficacy

Itzel Reneé Astiazarán-Rascón, Hsiou-Ting Kuo, Lily Li, Jutta Zeisler, Pauline Ng, Helen Merkens, Joseph Lau, Kuo-Shyan Lin, François Bénard

Molecular Pharmaceutics · 11.11.2026

DOI: 10.1021/acs.molpharmaceut.6c00931 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Pharmaceutics, online erschienen am 11.11.2026. Verfasst von Itzel Reneé Astiazarán-Rascón und 8 weiteren Autor:innen. Die Arbeit nennt 57 Literaturangaben. Gefördert von: Canadian Institutes of Health Research (CIHR), New Frontiers in Research Fund.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Radioligands targeting the C-X-C Chemokine Receptor 4 (CXCR4) are promising for the diagnosis and therapy of multiple tumor types. The therapeutic efficacy of radiopharmaceutical therapy can be enhanced by albumin binders, which modulate the plasma half-life of radioligands and can increase tumor uptake. We report a novel class of CXCR4-targeting radioligands conjugated to non-covalent albumin binders with improved tumor uptake and prolonged tumor retention in a lymphoma model. Four 4-phenylbutyric acid (4-PBA) derivatives with p-MeO, p-Cl, p-Br, or p-I substituents were selected as albumin-binding motifs and coupled to a novel CXCR4-binding cyclic peptide. All non-radioactive standards were obtained with high purity (>95%) and showed high specific binding to CXCR4 as measured by the radioligand competition assay. Four peptides were labeled with [177Lu]LuCl3, with >94% radiochemical purity. Biodistribution and longitudinal SPECT imaging studies showed that variations in albumin binder substituents modulated the plasma half-life of CXCR4-targeting radioligands and improved tumor uptake. [177Lu]Lu-6, a peptide coupled to a 4-BrPBA albumin binder, showed high tumor uptake and tumor-to-organ ratios optimal for therapeutic studies. [177Lu]Lu-6 tumor uptake reached 23.6 ± 4.57% injected activity per gram (% IA/g) at 24 h post-injection, with persistent uptake (12.3 ± 2.04 % IA/g) after 120 h. Blood and kidney uptake were 0.28 ± 0.03 and 1.14 ± 0.08 % IA/g at 24 h, respectively. In a therapy study, [177Lu]Lu-6 (15, 30, and 60 MBq) resulted in potent tumor growth inhibition and increased overall survival in a Z138 xenograft model in comparison to the control and [177Lu]Lu-Pentixather groups (p < 0.05). Novel CXCR4 radioligands coupled to albumin binders demonstrated high and prolonged tumor uptake in a CXCR4-expressing tumor model. [177Lu]Lu-6 achieved an excellent balance between maximizing tumor uptake while keeping the blood residence time sufficiently short to avoid excessive exposure to normal organs.

Förderung

  • Canadian Institutes of Health Research (CIHR)
  • New Frontiers in Research Fund

Zitieren

APA

Astiazarán-Rascón, I. R., Kuo, H., Li, L., Zeisler, J., Ng, P., Merkens, H., Lau, J., Lin, K., & Bénard, F. (2026). Novel CXCR4-Targeted Radioligands with Improved Tumor Uptake and Therapeutic Efficacy. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.6c00931

Vancouver

Astiazarán-Rascón IR, Kuo H, Li L, Zeisler J, Ng P, Merkens H, et al. Novel CXCR4-Targeted Radioligands with Improved Tumor Uptake and Therapeutic Efficacy. Molecular Pharmaceutics. 2026. doi:10.1021/acs.molpharmaceut.6c00931

BibTeX
@article{AstiazaranRascon2026,
  author = {Astiazarán-Rascón, Itzel Reneé and Kuo, Hsiou-Ting and Li, Lily and Zeisler, Jutta and Ng, Pauline and Merkens, Helen and Lau, Joseph and Lin, Kuo-Shyan and Bénard, François},
  title = {Novel CXCR4-Targeted Radioligands with Improved Tumor Uptake and Therapeutic Efficacy},
  journal = {Molecular Pharmaceutics},
  year = {2026},
  doi = {10.1021/acs.molpharmaceut.6c00931}
}
Kostenlos starten →